Publications by authors named "Wendy Vermeulen"
Purpose: This phase I study assessed the maximum tolerated dose (MTD), safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of SJG-136, a sequence-specific DNA cross-linking agent, in patients with advanced cancer.
Experimental Design: In schedule A, seven patients received escalating doses of SJG-136 (6, 12, 24, and 48 μg/m(2)) daily for 5 of 21 days. Blood samples were collected for PK analysis on days 1 and 5 of cycle 1.
Objectives: The thioxanthone analog, SR271425, is a novel cytotoxic DNA-interacting agent with broad antitumor activity in preclinical models. The objectives of this phase I study were to determine the dose-limiting toxicities, maximum tolerated dose, recommended phase II dose, pharmacokinetic profile, and trend for efficacy in patients with advanced cancer.
Methods: SR271425 was administered intravenously over 1-hour, weekly for 2 weeks, followed by 1 week rest.
Article Synopsis
- The study aimed to evaluate the safety and pharmacokinetics of a new cancer treatment, OSI-7904L, when combined with cisplatin in adults with advanced solid tumors.
- The treatment was administered in various doses, and while some patients experienced dose-limiting toxicities, the most severe was managed, leading to an identified recommended dose for future studies.
- Preliminary signs of effectiveness were noted in some breast and gastric cancer patients, with no major drug interaction between the two agents.
Objectives: This phase I study was conducted to evaluate the combination of irinotecan, a topoisomerase I inhibitor, with epirubicin, a topoisomerase II inhibitor, when administered sequentially on a once-every-three week basis.
Methods: Irinotecan was administered at doses ranging from 100 to 150 mg/m(2) intravenously over 90 minutes, 24 hours before epirubicin, in doses from 30 to 60 mg/m(2), every 3 weeks. Toxicity assessments were performed weekly.